HIV-1逆转录酶E138A天然多态性体外降低依曲韦林耐药遗传屏障
该体外研究用20株临床重组病毒及NL4-3克隆,在递增依曲韦林浓度下培养,比较138E与138A的耐药选择。结果显示138A病毒对依曲韦林敏感性更低、更早突破药物压力、可在更高药物浓度下生长,提示E138A通过降低耐药遗传屏障削弱依曲韦林应答。
要点
- E138A可降低依曲韦林耐药遗传屏障,导致体外应答减弱
- 不同基因型耐药算法对E138A的依曲韦林解读不一致
- 体外耐药选择可补充评估低水平耐药突变的完整潜力
核心结论
- E138A可通过降低耐药遗传屏障导致依曲韦林应答减弱。
- 体外药物耐药选择是界定低水平耐药突变完整潜力的有价值补充。
研究设计与样本
- 研究纳入20株临床来源重组病毒,其中10株为WT 138E、10株为138A,均无其他耐药突变。
- 病毒在递增依曲韦林浓度下培养,突破时分析基因型变化。
- 平行实验使用138E/A/G/K/Q的NL4-3基础克隆。
主要发现
- NL4-3背景中,138位密码子改变对依曲韦林耐药的增加顺序为Q > K > A > G > E。
- 138A病毒较138E病毒敏感性更低,中位(IQR)倍数变化为1.8(1.5-2.8)对1.3(0.8-1.8),P = 0.026。
- 138A更早突破依曲韦林压力,病毒生长HR(95%CI)为5.48(2.95-28.24),P < 0.001。
- 138A在更高药物浓度下生长,中位(IQR)为1350(1350-1350)对0(0-1350)nM,P = 0.005。
- 多种依曲韦林耐药相关突变及RT连接区和RNase H结构域变化累积,无随基线138位密码子的一致模式。
临床怎么用
- 解读依曲韦林耐药时需关注E138A对遗传屏障的影响,不宜仅按单一算法判定敏感。
- 对携带E138A且无其他耐药突变的HIV-1,应结合体外耐药选择证据评估依曲韦林应答。
- 不同基因型耐药算法对E138A解读不一致时,可参考降低遗传屏障的体外证据辅助决策。
局限性
- 结果为体外实验,临床相关性需进一步验证。
- 研究未涉及依曲韦林具体剂量或阈值推荐。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The HIV-1 reverse transcriptase (RT) natural polymorphism E138A is included among the mutations with a minor impact on response to etravirine. However, the interpretation of E138A on etravirine susceptibility is not consistent across different genotypic resistance algorithms. The aim of the study was to investigate the effect of E138A on the genetic barrier to resistance to etravirine in vitro. METHODS: A panel of 20 clinically derived recombinant viruses (10 with WT 138E and 10 with 138A, all without any other resistance mutation) were cultured in the presence of increasing etravirine concentrations and analysed for genotypic changes at virus breakthrough. Parallel experiments were conducted with 138E/A/G/K/Q NL4-3-based clones. RESULTS: In the NL4-3 background, codon 138 changes increased etravirine resistance in the following order: Q > K > A > G > E. The 138A viruses were less susceptible to etravirine compared with the 138E viruses [median (IQR) fold change, 1.8 (1.5-2.8) versus 1.3 (0.8-1.8); P = 0.026], overcame etravirine pressure earlier [HR (95% CI) for viral outgrowth with 138A, 5.48 (2.95-28.24); P < 0.001] and grew at higher drug concentrations [median (IQR), 1350 (1350-1350) versus 0 (0-1350) nM; P = 0.005]. A variety of etravirine resistance-related mutations and changes in the RT connection and RNase H domains accumulated without any consistent pattern depending on baseline codon 138. CONCLUSIONS: E138A can contribute to reduced response to etravirine through a decreased genetic barrier to resistance. In vitro drug resistance selection is a valuable complement to define the full potential of low-level resistance mutations.
引用
- Giannini A, Vicenti I, Materazzi A, et al. The HIV-1 reverse transcriptase E138A natural polymorphism decreases the genetic barrier to resistance to etravirine in vitro. J Antimicrob Chemother. 2019. PMID: 30462235. doi:10.1093/jac/dky479
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。